

CONTACT: Hiroyuki Miyanohara, Corporate Communication Japan
(hiroyuki.miyanohara@quintiles.com) +81 3 6894 - 0149

QUINTILES' JAPANESE CENTRAL LABORATORY EXPANDS and ADDS NEW TECHNOLOGY

Part of world's largest network of CAP-accredited, fully harmonized central labs

TOKYO— April 5, 2011 – Quintiles today announced that its laboratory in Tokyo has expanded and added new technology to meet the growing demand for central laboratory services in Japan.

The laboratory has expanded significantly (tripled in size) to allow increased capacity and productivity for sample processing. New flow cytometry capability has been added and molecular testing services using PCR (polymerase chain reaction) technologies will be implemented in the near future.

The laboratory based in Shinjuku, Tokyo, already has full capability to handle safety testing (Chemistry, Hematology, Urinalysis) plus coagulation in addition to Immunology and Special Chemistry. These enhancements further strengthen Quintiles' ability to offer world-class, globally harmonized laboratory services for the Japanese market, while accommodating global and regional trials.

Quintiles began providing central laboratory services in Japan in 2008 and opened its own central laboratory in Tokyo in March 2010 to bolster its capability to efficiently serve customers in Japan and the Asia-Pacific region. The laboratory employs a full team comprising medical technologists, specimen management personnel, project management as well as investigator/site support and QA and received accreditation from both the College of American Pathologists (CAP) in September 2010 as well as NGSP Level 1 Laboratory (the highest level of National Glycohemoglobin Standardization Program) in March 2010. These are important qualifications for the general conduct of clinical trials and testing for HbA1c (diabetes studies) respectively.

“This is a key milestone for us in meeting the needs of customers and patients in clinical trials,” said Madonna Kim, Quintiles Global Central Laboratories in Japan. “Despite the recent events in Japan, we were able to move forward with our expansion plans while continuing to provide needed services to our customers and patients. I’m very proud of our experienced, committed staff members who executed our detailed business continuity plan and kept our commitments to customers and patients.”

Alan Ong, Vice President and General Manager, Quintiles Global Central Laboratories Asia, said: “The lab in Japan is a key part of our network in Asia that includes labs in Singapore, China and India, each meeting the unique needs of those marketplaces. This network allows us to meet customer needs locally, regionally and globally to help customers get new medicines to patients faster.”

About Quintiles

Quintiles is the only fully integrated biopharmaceutical services company offering [clinical](#), [commercial](#), [consulting](#) and [capital](#) solutions worldwide. The Quintiles network of more than 20,000 engaged professionals in 60 countries works with an unwavering commitment to patients, safety and ethics. Quintiles helps biopharmaceutical companies navigate risk and seize opportunities in an environment where change is constant. For more information, please visit www.quintiles.com.